Galapagos NV, the Belgian company that develops genomics-based drugs, is delisting its shares on Britain’s Alternative Investment Market (AIM) and offering a facility for trading the shares in the US over-the-counter market through the issuance of American Depository Receipts (ADRs). The company’s shares will continue to trade on the Euronext in Amsterdam and Brussels.
